Department of Medicine, Division of Infectious Diseases, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.
J Infect. 2010 May;60(5):386-96. doi: 10.1016/j.jinf.2010.02.009. Epub 2010 Feb 20.
The use of anti-tumor necrosis factor agents such as infliximab as treatment modalities of inflammatory joint diseases has widely spread over the past few years. However, increasing numbers of reports of infectious complications during TNF-a blockade have also highlighted the fact that an increased rate of sometimes life-threatening complications may be the price paid for superior therapeutic efficacy. We report the first case report of Listeria endocarditis associated with infliximab use and the second published case of Listeria infection associated with infliximab in patients with psoriatic arthritis. We also summarize the literature regarding the association of Listeria infection with use of infliximab. Further studies are needed to elucidate the contribution of anti-TNF-a therapy to development of listeriosis. Physicians should be aware of the possibility of Listeria infection in individuals receiving anti-TNF therapy.
在过去的几年中，使用抗肿瘤坏死因子（TNF）药物，如英夫利昔单抗，作为治疗炎症性关节疾病的方法已经得到了广泛的应用。然而，越来越多的报告表明，在 TNF-α阻断期间会发生感染性并发症，这也凸显了一个事实，即有时可能危及生命的并发症发生率增加可能是为了获得更好的治疗效果而付出的代价。我们报告了首例与英夫利昔单抗使用相关的李斯特菌心内膜炎病例，也是第二例与英夫利昔单抗使用相关的、发生在银屑病关节炎患者中的李斯特菌感染病例。我们还总结了与李斯特菌感染与英夫利昔单抗使用相关的文献。需要进一步的研究来阐明抗 TNF-α治疗对李斯特菌病发展的影响。医生应该意识到接受抗 TNF 治疗的个体中存在李斯特菌感染的可能性。
